<scp>TNF</scp> inhibitors and cardiovascular risk: Friend or foe?-Reference-Cited by-同舟云学术

TNF inhibitors and cardiovascular risk: Friend or foe?

Published:2024-05-25 Issue:6 Volume:38 Page:995-996
ISSN:0926-9959
Container-title:Journal of the European Academy of Dermatology and Venereology
language:en
Short-container-title:Acad Dermatol Venereol

Author:

Gelfand Joel M.¹,Garshick Michael²³^ORCID

Affiliation:

1. Department of Dermatology and Department of Biostatistics, Epidemiology, and Informatics Center for Clinical Sciences in Dermatology University of Pennsylvania Perelman School of Medicine Philadelphia Pennsylvania USA

2. Leon H. Charney Division of Cardiology, Department of Medicine NYU Grossman School of Medicine New York New York USA

3. Ronald O. Perelman Department of Dermatology NYU Grossman School of Medicine New York New York USA

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jdv.20017

Reference9 articles.

1. Risk of myocardial infarction in patients with psoriasis;Gelfand JM;JAMA,2006

2. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines;Grundy SM;J Am Coll Cardiol,2019

3. Low‐dose colchicine for secondary prevention of coronary artery disease: JACC review topic of the week;Nelson K;J Am Coll Cardiol,2023

4. Effect of 2 psoriasis treatments on vascular inflammation and novel inflammatory cardiovascular biomarkers: a randomized placebo‐controlled trial;Mehta NN;Circ Cardiovasc Imaging,2018

5. TNF‐alpha and heart failure. The difference between proof of principle and hypothesis testing;Francis GS;Circulation,1999